Literature DB >> 1393372

Antilactoferrin antibody in systemic lupus erythematosus.

S S Lee1, J W Lawton, C E Chan, C S Li, T H Kwan, K F Chau.   

Abstract

Lactoferrin is a secondary granule protein of neutrophils. Seventy-nine systemic lupus erythematosus patients who fulfilled the ARA criteria for classification were tested for antibody against human lactoferrin (LF-ab) by ELISA. Thirty-one of these (39.2%) demonstrated elevated levels. There was significant correlation between LF-ab positivity and disease duration. Clinical flare was common with positive LF-ab (P less than 0.05). Disease manifestations were independent of antibody status except for an increased incidence of lymphadenopathy and crescentic gomerulonephritis among those who had LF-ab. No consistent immunofluorescence pattern could be demonstrated on alcohol-fixed neutrophils for the LF-ab positive sera. It is suggested that LF-ab is related to lupus activity, and can be useful as a marker for disease monitoring.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1393372     DOI: 10.1093/rheumatology/31.10.669

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  18 in total

Review 1.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases.

Authors:  H Chikazawa; K Nishiya; A Matsumori; K Hashimoto
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

3.  Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features.

Authors:  K Nishiya; H Chikazawa; S Nishimura; N Hisakawa; K Hashimoto
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

Review 4.  The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens.

Authors:  A Wiik; L Stummann; L Kjeldsen; N Borregaard; S Ullman; S Jacobsen; P Halberg
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

5.  Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates.

Authors:  Domenico Caccavo; Amelia Rigon; Antonio Picardi; Sara Galluzzo; Marta Vadacca; Giovanni Maria Ferri; Antonio Amoroso; Antonella Afeltra
Journal:  Clin Rheumatol       Date:  2004-12-09       Impact factor: 2.980

Review 6.  Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.

Authors:  Feng Yu; Mark Haas; Richard Glassock; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

7.  Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  J A Savige; L Chang; D Wilson; R R Buchanan
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 8.  The clinical relevance of ANCA in vasculitis.

Authors:  W L Gross; S Hauschild; N Mistry
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

9.  Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity.

Authors:  Samih H Nasr; Vivette D D'Agati; Hye-Ran Park; Paul L Sterman; Juan D Goyzueta; Robert M Dressler; Shawn M Hazlett; Robert N Pursell; Christopher Caputo; Glen S Markowitz
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

10.  Antineutrophil cytoplasmic antibodies in childhood systemic lupus erythematosus.

Authors:  A Bakkaloglu; R Topaloglu; U Saatçi; S Ozdemir; S Ozen; Y Başsoy; N Beşbaş
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.